Related Experiment Video
Updated: May 21, 2025
Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
Published on: November 5, 2020
Examining the Use of Serum Biomarkers to Guide Early Detection of Pancreatic Cancer
1Christina Zhang.
Background:
Pancreatic cancer is estimated to become the second leading cause of cancer-related death by 2030 because of high malignancy, late diagnosis, inefficient therapy, and a lack of available screening for early detection.
Objectives:
This article presents current clinical data supporting the use of serum biomarker signatures as a modality for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and treatment.
Methods:
A clinical case study highlights the use of serum biomarker signatures in PDAC diagnosis. Clinical guidelines on PDAC were obtained from the National Comprehensive Cancer Network, the National Cancer Institute, StatPearls Publishing, the American Cancer Society, and the Pancreatic Cancer Detection Consortium.
Findings:
Screening barriers involve a low incidence and histologic heterogeneity of disease, as well as a need for prospective multicenter analysis of proposed biomarkers. Because the poor prognosis of PDAC is attributed to late detection, the development of a clinical guideline for biomarker-based screening warrants interprofessional awareness and advocacy in oncology clinical practice.
More Related Videos
10:34Measurement of Differentially Methylated INS DNA Species in Human Serum Samples as a Biomarker of Islet β Cell Death
Published on: December 21, 2016
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
